JAK Inhibitors as a Novel Approach to Autoimmune Bullous Diseases: A Review
Dermatologic Therapy, Volume 2026, Issue 1, 2026.Autoimmune bullous diseases (AIBDs) are a group of chronic disorders characterized by blister formation resulting from abnormal immune responses. Janus kinase (JAK) inhibitors have emerged as promising therapeutic agents for AIBDs. This review discusses the use of JAK inhibitors—such as upadacitinib, baricitinib, tofacitinib, and abrocitinib, among ...
Olga Olisova +9 more
wiley +1 more source
An Algorithm for the Diagnosis and Management of Severe Asthma in Children and Adolescents
Allergy, Volume 81, Issue 1, Page 307-310, January 2026.
Eckard Hamelmann +3 more
wiley +1 more source
Saisonale Schwankungen des Serum-IgE-Spiegels und deren mögliche Bedeutung für die Berechnung der therapeutischen Dosis von Omalizumab (rhuMab-E25, anti-IgE) [PDF]
, 2004 K.M. Beeh, Jutta Beier, Roland Buhl
openalex +1 more source
Omalizumab rapidly inhibits nasal allergic responses
, 2003 Huang-Shen Lin +4 more
openalex +1 more source
Allergy, Volume 81, Issue 1, Page 292-296, January 2026.
Stéphanie Wanin +12 more
wiley +1 more source
Early control or gradual relief? Gender-specific real-world insights into omalizumab response in chronic spontaneous urticaria patients. [PDF]
World Allergy Organ JPreis S +4 more
europepmc +1 more source
<i>Helicobacter pylori</i> and Cancer: What's the Link? [PDF]
Clin Exp GastroenterolMerola E, Pes GM, Graham DY, Dore MP.
europepmc +1 more source
Considerations for biologics as front-line treatment in allergic diseases. [PDF]
Front ImmunolKothari A, Hung L, Upton JEM.
europepmc +1 more source
Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial [PDF]
, 2017 Masaya Takahashi +9 more
openalex +1 more source